Roche's Financial Growth in Q1 2025

F. Hoffmann-La Roche AG announced a robust start to the fiscal year 2025, with first-quarter sales reaching 15.4 billion Swiss francs. This represents a 7% increase in Swiss francs and a 6% rise at constant exchange rates (CER) compared to the previous year.

Divisional Performance Highlights

The pharmaceuticals division saw an 8% growth at CER, achieving sales of 11.95 billion Swiss francs. Meanwhile, the diagnostics division maintained stability with sales of 3.49 billion Swiss francs, showing little change from 2024.

CEO's Vision and Future Investments

"We had a good start to the year with Group sales increasing by 6% at constant exchange rates and we achieved a number of important milestones," stated CEO Thomas Schinecker. He emphasized Roche's commitment to expanding its US presence, highlighting a planned investment of USD 50 billion to enhance its R&D and manufacturing capabilities, aiming to better serve patient needs with innovative solutions.